0.018866 0.000000 0.000000 0.000000 0.014063 0.000000 0.000000 0.000000 0.013883 0.00000 0.00000 0.00000 Wang, S. Griffiths, G. Midgley, C.A. Barnett, A.L. Cooper, M. Grabarek, J. Ingram, L. Jackson, W. Kontopidis, G. McClue, S.J. McInnes, C. McLachlan, J. Meades, C. Mezna, M. Stuart, I. Thomas, M.P. Zheleva, D.I. Lane, D.P. Jackson, R.C. Glover, D.M. Blake, D.G. Fischer, P.M. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 4 90.00 90.00 90.00 53.005 71.108 72.028 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking C19 H22 N6 O S 382.483 3,4-DIMETHYL-5-(2-{[(1Z)-4-PIPERAZIN-1-YLCYCLOHEXA-2,4-DIEN-1-YLIDENE]AMINO}PYRIMIDIN-4-YL)-1,3-THIAZOL-2(3H)-ONE non-polymer N 1 N N N 2 S C N 3 N C N 4 N O N 5 N C N 6 N O N 7 N H N 8 N H N 9 N H N 10 N H N 11 N H N 12 N H N 13 N H N 14 N N N 15 S C N 16 N C N 17 N O N 18 N C N 19 N C N 20 N C N 21 N N N 22 N C N 23 N N N 24 N N N 25 N O N 26 N H N 27 N H N 28 N H N 29 N H N 30 N H N 31 N H N 32 N H N 33 N H N 34 N H N 35 N H N 36 N H N 37 N H N 38 N H N 39 N H N 40 N H N 41 N N N 42 S C N 43 N C N 44 N O N 45 N C N 46 N C N 47 N O N 48 N N N 49 N O N 50 N H N 51 N H N 52 N H N 53 N H N 54 N H N 55 N H N 56 N H N 57 N H N 58 N N N 59 S C N 60 N C N 61 N O N 62 N C N 63 N C N 64 N O N 65 N O N 66 N O N 67 N H N 68 N H N 69 N H N 70 N H N 71 N H N 72 N H N 73 N H N 74 N N N 75 R C N 76 N C N 77 N O N 78 N C N 79 N S N 80 N O N 81 N H N 82 N H N 83 N H N 84 N H N 85 N H N 86 N H N 87 N H N 88 N N N 89 S C N 90 N C N 91 N O N 92 N C N 93 N C N 94 N C N 95 N O N 96 N N N 97 N O N 98 N H N 99 N H N 100 N H N 101 N H N 102 N H N 103 N H N 104 N H N 105 N H N 106 N H N 107 N H N 108 N N N 109 S C N 110 N C N 111 N O N 112 N C N 113 N C N 114 N C N 115 N O N 116 N O N 117 N O N 118 N H N 119 N H N 120 N H N 121 N H N 122 N H N 123 N H N 124 N H N 125 N H N 126 N H N 127 N N N 128 N C N 129 N C N 130 N O N 131 N O N 132 N H N 133 N H N 134 N H N 135 N H N 136 N H N 137 N N N 138 S C N 139 N C N 140 N O N 141 N C Y 142 N C Y 143 N N Y 144 N C Y 145 N C Y 146 N N N 147 N O N 148 N H N 149 N H N 150 N H N 151 N H N 152 N H N 153 N H N 154 N H N 155 N H N 156 N H N 157 N H N 158 N O N 159 N H N 160 N H N 161 N N N 162 S C N 163 N C N 164 N O N 165 S C N 166 N C N 167 N C N 168 N C N 169 N O N 170 N H N 171 N H N 172 N H N 173 N H N 174 N H N 175 N H N 176 N H N 177 N H N 178 N H N 179 N H N 180 N H N 181 N H N 182 N H N 183 N N N 184 S C N 185 N C N 186 N O N 187 N C N 188 N C N 189 N C N 190 N C N 191 N O N 192 N H N 193 N H N 194 N H N 195 N H N 196 N H N 197 N H N 198 N H N 199 N H N 200 N H N 201 N H N 202 N H N 203 N H N 204 N H N 205 N N N 206 S C N 207 N C N 208 N O N 209 N C N 210 N C N 211 N C N 212 N C N 213 N N N 214 N O N 215 N H N 216 N H N 217 N H N 218 N H N 219 N H N 220 N H N 221 N H N 222 N H N 223 N H N 224 N H N 225 N H N 226 N H N 227 N H N 228 N H N 229 N H N 230 N N N 231 S C N 232 N C N 233 N O N 234 N C N 235 N C N 236 N S N 237 N C N 238 N O N 239 N H N 240 N H N 241 N H N 242 N H N 243 N H N 244 N H N 245 N H N 246 N H N 247 N H N 248 N H N 249 N H N 250 N N N 251 S C N 252 N C N 253 N O N 254 N C Y 255 N C Y 256 N C Y 257 N C Y 258 N C Y 259 N C Y 260 N C N 261 N O N 262 N H N 263 N H N 264 N H N 265 N H N 266 N H N 267 N H N 268 N H N 269 N H N 270 N H N 271 N H N 272 N H N 273 N N N 274 S C N 275 N C N 276 N O N 277 N C N 278 N C N 279 N C N 280 N O N 281 N H N 282 N H N 283 N H N 284 N H N 285 N H N 286 N H N 287 N H N 288 N H N 289 N H N 290 N N N 291 S C N 292 N C N 293 N O N 294 N C N 295 N O N 296 N O N 297 N H N 298 N H N 299 N H N 300 N H N 301 N H N 302 N H N 303 N H N 304 N N N 305 S C N 306 N C N 307 N O N 308 R C N 309 N O N 310 N C N 311 N O N 312 N H N 313 N H N 314 N H N 315 N H N 316 N H N 317 N H N 318 N H N 319 N H N 320 N H N 321 N N N 322 S C N 323 N C N 324 N O N 325 N C Y 326 N C Y 327 N C Y 328 N C Y 329 N N Y 330 N C Y 331 N C Y 332 N C Y 333 N C Y 334 N C N 335 N O N 336 N H N 337 N H N 338 N H N 339 N H N 340 N H N 341 N H N 342 N H N 343 N H N 344 N H N 345 N H N 346 N H N 347 N H N 348 N N N 349 S C N 350 N C N 351 N O N 352 N C Y 353 N C Y 354 N C Y 355 N C Y 356 N C Y 357 N C Y 358 N C N 359 N O N 360 N O N 361 N H N 362 N H N 363 N H N 364 N H N 365 N H N 366 N H N 367 N H N 368 N H N 369 N H N 370 N H N 371 N H N 372 N N N 373 S C N 374 N C N 375 N O N 376 N C N 377 N C N 378 N C N 379 N O N 380 N H N 381 N H N 382 N H N 383 N H N 384 N H N 385 N H N 386 N H N 387 N H N 388 N H N 389 N H N 390 N H N 391 N C N 392 N C N 393 N N N 394 N C N 395 N C N 396 N N N 397 N C N 398 N C N 399 N C N 400 N C N 401 N C N 402 N C N 403 N N Y 404 N C Y 405 N N Y 406 N N Y 407 N C Y 408 N C Y 409 N C N 410 N C N 411 N S N 412 N C N 413 N O N 414 N N N 415 N C N 416 N C N 417 N C N 418 N H N 419 N H N 420 N H N 421 N H N 422 N H N 423 N H N 424 N H N 425 N H N 426 N H N 427 N H N 428 N H N 429 N H N 430 N H N 431 N H N 432 N H N 433 N H N 434 N H N 435 N H N 436 N H N 437 N H N 438 N H N 439 N H N 1 N sing N 2 N sing N 3 N sing N 4 N sing N 5 N sing N 6 N sing N 7 N doub N 8 N sing N 9 N sing N 10 N sing N 11 N sing N 12 N sing N 13 N sing N 14 N sing N 15 N sing N 16 N sing N 17 N sing N 18 N sing N 19 N doub N 20 N sing N 21 N sing N 22 N sing N 23 N sing N 24 N sing N 25 N sing N 26 N sing N 27 N sing N 28 N sing N 29 N sing N 30 N sing N 31 N sing N 32 N sing N 33 N doub N 34 N sing N 35 N sing N 36 N sing N 37 N sing N 38 N sing N 39 N sing N 40 N sing N 41 N sing N 42 N sing N 43 N sing N 44 N sing N 45 N doub N 46 N sing N 47 N sing N 48 N sing N 49 N sing N 50 N doub N 51 N sing N 52 N sing N 53 N sing N 54 N sing N 55 N sing N 56 N sing N 57 N sing N 58 N sing N 59 N sing N 60 N sing N 61 N doub N 62 N sing N 63 N sing N 64 N sing N 65 N sing N 66 N doub N 67 N sing N 68 N sing N 69 N sing N 70 N sing N 71 N sing N 72 N sing N 73 N sing N 74 N sing N 75 N sing N 76 N doub N 77 N sing N 78 N sing N 79 N sing N 80 N sing N 81 N sing N 82 N sing N 83 N sing N 84 N sing N 85 N sing N 86 N sing N 87 N sing N 88 N sing N 89 N doub N 90 N sing N 91 N sing N 92 N sing N 93 N sing N 94 N sing N 95 N sing N 96 N sing N 97 N doub N 98 N sing N 99 N sing N 100 N sing N 101 N sing N 102 N sing N 103 N sing N 104 N sing N 105 N sing N 106 N sing N 107 N sing N 108 N doub N 109 N sing N 110 N sing N 111 N sing N 112 N sing N 113 N sing N 114 N sing N 115 N sing N 116 N doub N 117 N sing N 118 N sing N 119 N sing N 120 N sing N 121 N sing N 122 N sing N 123 N sing N 124 N sing N 125 N sing N 126 N doub N 127 N sing N 128 N sing N 129 N sing N 130 N sing N 131 N sing N 132 N sing N 133 N sing N 134 N sing N 135 N doub N 136 N sing N 137 N sing N 138 N sing N 139 N sing Y 140 N sing Y 141 N doub Y 142 N doub N 143 N sing Y 144 N sing N 145 N sing Y 146 N sing N 147 N sing N 148 N sing N 149 N sing N 150 N sing N 151 N sing N 152 N sing N 153 N sing N 154 N sing N 155 N sing N 156 N sing N 157 N sing N 158 N doub N 159 N sing N 160 N sing N 161 N sing N 162 N sing N 163 N sing N 164 N sing N 165 N sing N 166 N sing N 167 N sing N 168 N sing N 169 N sing N 170 N sing N 171 N sing N 172 N sing N 173 N sing N 174 N sing N 175 N sing N 176 N sing N 177 N sing N 178 N sing N 179 N doub N 180 N sing N 181 N sing N 182 N sing N 183 N sing N 184 N sing N 185 N sing N 186 N sing N 187 N sing N 188 N sing N 189 N sing N 190 N sing N 191 N sing N 192 N sing N 193 N sing N 194 N sing N 195 N sing N 196 N sing N 197 N sing N 198 N sing N 199 N sing N 200 N doub N 201 N sing N 202 N sing N 203 N sing N 204 N sing N 205 N sing N 206 N sing N 207 N sing N 208 N sing N 209 N sing N 210 N sing N 211 N sing N 212 N sing N 213 N sing N 214 N sing N 215 N sing N 216 N sing N 217 N sing N 218 N sing N 219 N sing N 220 N sing N 221 N sing N 222 N sing N 223 N sing N 224 N doub N 225 N sing N 226 N sing N 227 N sing N 228 N sing N 229 N sing N 230 N sing N 231 N sing N 232 N sing N 233 N sing N 234 N sing N 235 N sing N 236 N sing N 237 N sing N 238 N sing N 239 N sing N 240 N sing N 241 N sing N 242 N sing N 243 N doub N 244 N sing N 245 N sing N 246 N sing N 247 N sing Y 248 N doub Y 249 N sing Y 250 N sing N 251 N sing Y 252 N doub N 253 N sing Y 254 N doub N 255 N sing Y 256 N sing N 257 N sing N 258 N sing N 259 N sing N 260 N sing N 261 N sing N 262 N sing N 263 N sing N 264 N sing N 265 N sing N 266 N doub N 267 N sing N 268 N sing N 269 N sing N 270 N sing N 271 N sing N 272 N sing N 273 N sing N 274 N sing N 275 N sing N 276 N sing N 277 N sing N 278 N sing N 279 N sing N 280 N sing N 281 N sing N 282 N sing N 283 N doub N 284 N sing N 285 N sing N 286 N sing N 287 N sing N 288 N sing N 289 N sing N 290 N sing N 291 N sing N 292 N sing N 293 N sing N 294 N sing N 295 N sing N 296 N doub N 297 N sing N 298 N sing N 299 N sing N 300 N sing N 301 N sing N 302 N sing N 303 N sing N 304 N sing N 305 N sing N 306 N sing N 307 N sing N 308 N sing N 309 N sing N 310 N sing N 311 N sing N 312 N doub N 313 N sing N 314 N sing N 315 N sing N 316 N sing Y 317 N doub Y 318 N sing Y 319 N sing N 320 N sing Y 321 N doub Y 322 N sing Y 323 N sing N 324 N sing Y 325 N sing Y 326 N doub N 327 N sing Y 328 N doub N 329 N sing Y 330 N sing N 331 N sing N 332 N sing N 333 N sing N 334 N sing N 335 N sing N 336 N sing N 337 N sing N 338 N sing N 339 N sing N 340 N doub N 341 N sing N 342 N sing N 343 N sing N 344 N sing Y 345 N doub Y 346 N sing Y 347 N sing N 348 N sing Y 349 N doub N 350 N sing Y 351 N doub N 352 N sing Y 353 N sing N 354 N sing N 355 N sing N 356 N sing N 357 N sing N 358 N sing N 359 N sing N 360 N sing N 361 N sing N 362 N sing N 363 N sing N 364 N doub N 365 N sing N 366 N sing N 367 N sing N 368 N sing N 369 N sing N 370 N sing N 371 N sing N 372 N sing N 373 N sing N 374 N sing N 375 N sing N 376 N sing N 377 N sing N 378 N sing N 379 N sing N 380 N sing N 381 N sing N 382 N sing N 383 N sing N 384 N doub N 385 N doub N 386 N sing N 387 N sing N 388 N sing N 389 N doub N 390 N sing Y 391 N sing Y 392 N doub Y 393 N doub Y 394 N sing Y 395 N doub Y 396 N sing N 397 N sing N 398 N sing N 399 N doub N 400 N sing N 401 N doub N 402 N sing N 403 N sing N 404 N sing N 405 N sing N 406 N sing N 407 N sing N 408 N sing N 409 N sing N 410 N sing N 411 N sing N 412 N sing N 413 N sing N 414 N sing N 415 N sing N 416 N sing N 417 N sing N 418 N sing N 419 N sing N 420 N sing N 421 N sing N 422 N sing N 423 N sing N 424 N sing N 425 N sing N 426 N sing N 427 N sing UK Chem.Biol. CBOLE2 2050 1074-5521 17 1111 10.1016/J.CHEMBIOL.2010.07.016 21035734 Discovery and Characterisation of 2-Anilino-4-(Thiazol-5-Yl)Pyrimidine Transcriptional Cdk Inhibitors as Anticancer Agents 2010 10.2210/pdb2xnb/pdb pdb_00002xnb 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 100 1 BLUE MAX-FLUX CONFOCAL IMAGE PLATE 2004-07-30 RIGAKU IMAGE PLATE SINGLE WAVELENGTH M x-ray 1 1.5418 1.0 1.5418 ROTATING ANODE RIGAKU FR-D 33976.488 CELL DIVISION PROTEIN KINASE 2 2.7.11.22 1 man polymer 382.483 3,4-DIMETHYL-5-(2-{[(1Z)-4-PIPERAZIN-1-YLCYCLOHEXA-2,4-DIEN-1-YLIDENE]AMINO}PYRIMIDIN-4-YL)-1,3-THIAZOL-2(3H)-ONE 1 syn non-polymer 18.015 water 260 nat water P33 PROTEIN KINASE no no MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVF EFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYT HEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSF PKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVF EFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYT HEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSF PKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN FALL ARMYWORM sample 9606 HOMO SAPIENS SF9 7108 SPODOPTERA FRUGIPERDA BACULOVIRUS 1 1.84 32.5 NONE 6.8 10% PEG 3350, NAF, PH 7.0 chem_comp_atom chem_comp_bond database_2 pdbx_database_status pdbx_initial_refinement_model struct_site repository Initial release Database references Other Source and taxonomy Version format compliance Data collection Database references Derived calculations Other Refinement description 1 0 2010-11-10 1 1 2012-03-28 1 2 2023-12-20 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_sf _struct_site.pdbx_auth_asym_id _struct_site.pdbx_auth_comp_id _struct_site.pdbx_auth_seq_id CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM E2F HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR 1ST PUBLICATION TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN 2ND PUBLICATION DESIGN, SYNTHESIS AND EVALUATION OF 2-METHYL- AND 2-AMINO-N-ARYL-4,5- DIHYDROTHIAZOLO (4,5-H)QUINAZOLIN-8-AMINES AS RING-CONSTRAINED 2-ANILINO-4-(THIAZOL-5 -YL)PYRIMIDINE CDK INHIBITORS IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE. STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5B HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2-AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)-AMINE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- DIHYDRO-1H-INDOLE HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9-TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR HUMAN CYCLIN-DEPENDENT KINASE 2 P27(KIP1)/CYCLIN A/CDK2 COMPLEX HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4-METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR HUMAN CYCLIN-DEPENDENT KINASE 2 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5C PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR HUMAN CYCLIN-DEPENDENT KINASE 2 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058 STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO (4,3-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO-1H- PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/ CYCLIN A INCOMPLEX WITH THE INHIBITOR NU6271 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2-YLAMINE AND MONOMERIC CDK2 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN CKSHS1 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4- YL UREA (AT9283), A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY DISCOVERY AND CHARACTERISATION OF 2-ANILINO- 4-(THIAZOL-5-YL)PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE DIN-101312 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO- INDIRUBINE CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4- C PYRAZOLES: IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5- SULPHONATE BOUND STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1,4-DIAMINE THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN COMPLEX WITH THE INHIBITOR H717 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)-AMINE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL)BENZENESULFONAMIDE CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR PDBE Y PDBE 2010-08-01 REL REL 1 A O HOH 2039 6.83 Y8L 3,4-DIMETHYL-5-(2-{[(1Z)-4-PIPERAZIN-1-YLCYCLOHEXA-2,4-DIEN-1-YLIDENE]AMINO}PYRIMIDIN-4-YL)-1,3-THIAZOL-2(3H)-ONE HOH water 2CLX PDB ENTRY 2CLX PDB experimental model Y8L 1299 2 Y8L Y8L 1299 A HOH 2001 3 HOH HOH 2001 A HOH 2002 3 HOH HOH 2002 A HOH 2003 3 HOH HOH 2003 A HOH 2004 3 HOH HOH 2004 A HOH 2005 3 HOH HOH 2005 A HOH 2006 3 HOH HOH 2006 A HOH 2007 3 HOH HOH 2007 A HOH 2008 3 HOH HOH 2008 A HOH 2009 3 HOH HOH 2009 A HOH 2010 3 HOH HOH 2010 A HOH 2011 3 HOH HOH 2011 A HOH 2012 3 HOH HOH 2012 A HOH 2013 3 HOH HOH 2013 A HOH 2014 3 HOH HOH 2014 A HOH 2015 3 HOH HOH 2015 A HOH 2016 3 HOH HOH 2016 A HOH 2017 3 HOH HOH 2017 A HOH 2018 3 HOH HOH 2018 A HOH 2019 3 HOH HOH 2019 A HOH 2020 3 HOH HOH 2020 A HOH 2021 3 HOH HOH 2021 A HOH 2022 3 HOH HOH 2022 A HOH 2023 3 HOH HOH 2023 A HOH 2024 3 HOH HOH 2024 A HOH 2025 3 HOH HOH 2025 A HOH 2026 3 HOH HOH 2026 A HOH 2027 3 HOH HOH 2027 A HOH 2028 3 HOH HOH 2028 A HOH 2029 3 HOH HOH 2029 A HOH 2030 3 HOH HOH 2030 A HOH 2031 3 HOH HOH 2031 A HOH 2032 3 HOH HOH 2032 A HOH 2033 3 HOH HOH 2033 A HOH 2034 3 HOH HOH 2034 A HOH 2035 3 HOH HOH 2035 A HOH 2036 3 HOH HOH 2036 A HOH 2037 3 HOH HOH 2037 A HOH 2038 3 HOH HOH 2038 A HOH 2039 3 HOH HOH 2039 A HOH 2040 3 HOH HOH 2040 A HOH 2041 3 HOH HOH 2041 A HOH 2042 3 HOH HOH 2042 A HOH 2043 3 HOH HOH 2043 A HOH 2044 3 HOH HOH 2044 A HOH 2045 3 HOH HOH 2045 A HOH 2046 3 HOH HOH 2046 A HOH 2047 3 HOH HOH 2047 A HOH 2048 3 HOH HOH 2048 A HOH 2049 3 HOH HOH 2049 A HOH 2050 3 HOH HOH 2050 A HOH 2051 3 HOH HOH 2051 A HOH 2052 3 HOH HOH 2052 A HOH 2053 3 HOH HOH 2053 A HOH 2054 3 HOH HOH 2054 A HOH 2055 3 HOH HOH 2055 A HOH 2056 3 HOH HOH 2056 A HOH 2057 3 HOH HOH 2057 A HOH 2058 3 HOH HOH 2058 A HOH 2059 3 HOH HOH 2059 A HOH 2060 3 HOH HOH 2060 A HOH 2061 3 HOH HOH 2061 A HOH 2062 3 HOH HOH 2062 A HOH 2063 3 HOH HOH 2063 A HOH 2064 3 HOH HOH 2064 A HOH 2065 3 HOH HOH 2065 A HOH 2066 3 HOH HOH 2066 A HOH 2067 3 HOH HOH 2067 A HOH 2068 3 HOH HOH 2068 A HOH 2069 3 HOH HOH 2069 A HOH 2070 3 HOH HOH 2070 A HOH 2071 3 HOH HOH 2071 A HOH 2072 3 HOH HOH 2072 A HOH 2073 3 HOH HOH 2073 A HOH 2074 3 HOH HOH 2074 A HOH 2075 3 HOH HOH 2075 A HOH 2076 3 HOH HOH 2076 A HOH 2077 3 HOH HOH 2077 A HOH 2078 3 HOH HOH 2078 A HOH 2079 3 HOH HOH 2079 A HOH 2080 3 HOH HOH 2080 A HOH 2081 3 HOH HOH 2081 A HOH 2082 3 HOH HOH 2082 A HOH 2083 3 HOH HOH 2083 A HOH 2084 3 HOH HOH 2084 A HOH 2085 3 HOH HOH 2085 A HOH 2086 3 HOH HOH 2086 A HOH 2087 3 HOH HOH 2087 A HOH 2088 3 HOH HOH 2088 A HOH 2089 3 HOH HOH 2089 A HOH 2090 3 HOH HOH 2090 A HOH 2091 3 HOH HOH 2091 A HOH 2092 3 HOH HOH 2092 A HOH 2093 3 HOH HOH 2093 A HOH 2094 3 HOH HOH 2094 A HOH 2095 3 HOH HOH 2095 A HOH 2096 3 HOH HOH 2096 A HOH 2097 3 HOH HOH 2097 A HOH 2098 3 HOH HOH 2098 A HOH 2099 3 HOH HOH 2099 A HOH 2100 3 HOH HOH 2100 A HOH 2101 3 HOH HOH 2101 A HOH 2102 3 HOH HOH 2102 A HOH 2103 3 HOH HOH 2103 A HOH 2104 3 HOH HOH 2104 A HOH 2105 3 HOH HOH 2105 A HOH 2106 3 HOH HOH 2106 A HOH 2107 3 HOH HOH 2107 A HOH 2108 3 HOH HOH 2108 A HOH 2109 3 HOH HOH 2109 A HOH 2110 3 HOH HOH 2110 A HOH 2111 3 HOH HOH 2111 A HOH 2112 3 HOH HOH 2112 A HOH 2113 3 HOH HOH 2113 A HOH 2114 3 HOH HOH 2114 A HOH 2115 3 HOH HOH 2115 A HOH 2116 3 HOH HOH 2116 A HOH 2117 3 HOH HOH 2117 A HOH 2118 3 HOH HOH 2118 A HOH 2119 3 HOH HOH 2119 A HOH 2120 3 HOH HOH 2120 A HOH 2121 3 HOH HOH 2121 A HOH 2122 3 HOH HOH 2122 A HOH 2123 3 HOH HOH 2123 A HOH 2124 3 HOH HOH 2124 A HOH 2125 3 HOH HOH 2125 A HOH 2126 3 HOH HOH 2126 A HOH 2127 3 HOH HOH 2127 A HOH 2128 3 HOH HOH 2128 A HOH 2129 3 HOH HOH 2129 A HOH 2130 3 HOH HOH 2130 A HOH 2131 3 HOH HOH 2131 A HOH 2132 3 HOH HOH 2132 A HOH 2133 3 HOH HOH 2133 A HOH 2134 3 HOH HOH 2134 A HOH 2135 3 HOH HOH 2135 A HOH 2136 3 HOH HOH 2136 A HOH 2137 3 HOH HOH 2137 A HOH 2138 3 HOH HOH 2138 A HOH 2139 3 HOH HOH 2139 A HOH 2140 3 HOH HOH 2140 A HOH 2141 3 HOH HOH 2141 A HOH 2142 3 HOH HOH 2142 A HOH 2143 3 HOH HOH 2143 A HOH 2144 3 HOH HOH 2144 A HOH 2145 3 HOH HOH 2145 A HOH 2146 3 HOH HOH 2146 A HOH 2147 3 HOH HOH 2147 A HOH 2148 3 HOH HOH 2148 A HOH 2149 3 HOH HOH 2149 A HOH 2150 3 HOH HOH 2150 A HOH 2151 3 HOH HOH 2151 A HOH 2152 3 HOH HOH 2152 A HOH 2153 3 HOH HOH 2153 A HOH 2154 3 HOH HOH 2154 A HOH 2155 3 HOH HOH 2155 A HOH 2156 3 HOH HOH 2156 A HOH 2157 3 HOH HOH 2157 A HOH 2158 3 HOH HOH 2158 A HOH 2159 3 HOH HOH 2159 A HOH 2160 3 HOH HOH 2160 A HOH 2161 3 HOH HOH 2161 A HOH 2162 3 HOH HOH 2162 A HOH 2163 3 HOH HOH 2163 A HOH 2164 3 HOH HOH 2164 A HOH 2165 3 HOH HOH 2165 A HOH 2166 3 HOH HOH 2166 A HOH 2167 3 HOH HOH 2167 A HOH 2168 3 HOH HOH 2168 A HOH 2169 3 HOH HOH 2169 A HOH 2170 3 HOH HOH 2170 A HOH 2171 3 HOH HOH 2171 A HOH 2172 3 HOH HOH 2172 A HOH 2173 3 HOH HOH 2173 A HOH 2174 3 HOH HOH 2174 A HOH 2175 3 HOH HOH 2175 A HOH 2176 3 HOH HOH 2176 A HOH 2177 3 HOH HOH 2177 A HOH 2178 3 HOH HOH 2178 A HOH 2179 3 HOH HOH 2179 A HOH 2180 3 HOH HOH 2180 A HOH 2181 3 HOH HOH 2181 A HOH 2182 3 HOH HOH 2182 A HOH 2183 3 HOH HOH 2183 A HOH 2184 3 HOH HOH 2184 A HOH 2185 3 HOH HOH 2185 A HOH 2186 3 HOH HOH 2186 A HOH 2187 3 HOH HOH 2187 A HOH 2188 3 HOH HOH 2188 A HOH 2189 3 HOH HOH 2189 A HOH 2190 3 HOH HOH 2190 A HOH 2191 3 HOH HOH 2191 A HOH 2192 3 HOH HOH 2192 A HOH 2193 3 HOH HOH 2193 A HOH 2194 3 HOH HOH 2194 A HOH 2195 3 HOH HOH 2195 A HOH 2196 3 HOH HOH 2196 A HOH 2197 3 HOH HOH 2197 A HOH 2198 3 HOH HOH 2198 A HOH 2199 3 HOH HOH 2199 A HOH 2200 3 HOH HOH 2200 A HOH 2201 3 HOH HOH 2201 A HOH 2202 3 HOH HOH 2202 A HOH 2203 3 HOH HOH 2203 A HOH 2204 3 HOH HOH 2204 A HOH 2205 3 HOH HOH 2205 A HOH 2206 3 HOH HOH 2206 A HOH 2207 3 HOH HOH 2207 A HOH 2208 3 HOH HOH 2208 A HOH 2209 3 HOH HOH 2209 A HOH 2210 3 HOH HOH 2210 A HOH 2211 3 HOH HOH 2211 A HOH 2212 3 HOH HOH 2212 A HOH 2213 3 HOH HOH 2213 A HOH 2214 3 HOH HOH 2214 A HOH 2215 3 HOH HOH 2215 A HOH 2216 3 HOH HOH 2216 A HOH 2217 3 HOH HOH 2217 A HOH 2218 3 HOH HOH 2218 A HOH 2219 3 HOH HOH 2219 A HOH 2220 3 HOH HOH 2220 A HOH 2221 3 HOH HOH 2221 A HOH 2222 3 HOH HOH 2222 A HOH 2223 3 HOH HOH 2223 A HOH 2224 3 HOH HOH 2224 A HOH 2225 3 HOH HOH 2225 A HOH 2226 3 HOH HOH 2226 A HOH 2227 3 HOH HOH 2227 A HOH 2228 3 HOH HOH 2228 A HOH 2229 3 HOH HOH 2229 A HOH 2230 3 HOH HOH 2230 A HOH 2231 3 HOH HOH 2231 A HOH 2232 3 HOH HOH 2232 A HOH 2233 3 HOH HOH 2233 A HOH 2234 3 HOH HOH 2234 A HOH 2235 3 HOH HOH 2235 A HOH 2236 3 HOH HOH 2236 A HOH 2237 3 HOH HOH 2237 A HOH 2238 3 HOH HOH 2238 A HOH 2239 3 HOH HOH 2239 A HOH 2240 3 HOH HOH 2240 A HOH 2241 3 HOH HOH 2241 A HOH 2242 3 HOH HOH 2242 A HOH 2243 3 HOH HOH 2243 A HOH 2244 3 HOH HOH 2244 A HOH 2245 3 HOH HOH 2245 A HOH 2246 3 HOH HOH 2246 A HOH 2247 3 HOH HOH 2247 A HOH 2248 3 HOH HOH 2248 A HOH 2249 3 HOH HOH 2249 A HOH 2250 3 HOH HOH 2250 A HOH 2251 3 HOH HOH 2251 A HOH 2252 3 HOH HOH 2252 A HOH 2253 3 HOH HOH 2253 A HOH 2254 3 HOH HOH 2254 A HOH 2255 3 HOH HOH 2255 A HOH 2256 3 HOH HOH 2256 A HOH 2257 3 HOH HOH 2257 A HOH 2258 3 HOH HOH 2258 A HOH 2259 3 HOH HOH 2259 A HOH 2260 3 HOH HOH 2260 A MET 1 n 1 MET 1 A GLU 2 n 2 GLU 2 A ASN 3 n 3 ASN 3 A PHE 4 n 4 PHE 4 A GLN 5 n 5 GLN 5 A LYS 6 n 6 LYS 6 A VAL 7 n 7 VAL 7 A GLU 8 n 8 GLU 8 A LYS 9 n 9 LYS 9 A ILE 10 n 10 ILE 10 A GLY 11 n 11 GLY 11 A GLU 12 n 12 GLU 12 A GLY 13 n 13 GLY 13 A THR 14 n 14 THR 14 A TYR 15 n 15 TYR 15 A GLY 16 n 16 GLY 16 A VAL 17 n 17 VAL 17 A VAL 18 n 18 VAL 18 A TYR 19 n 19 TYR 19 A LYS 20 n 20 LYS 20 A ALA 21 n 21 ALA 21 A ARG 22 n 22 ARG 22 A ASN 23 n 23 ASN 23 A LYS 24 n 24 LYS 24 A LEU 25 n 25 LEU 25 A THR 26 n 26 THR 26 A GLY 27 n 27 GLY 27 A GLU 28 n 28 GLU 28 A VAL 29 n 29 VAL 29 A VAL 30 n 30 VAL 30 A ALA 31 n 31 ALA 31 A LEU 32 n 32 LEU 32 A LYS 33 n 33 LYS 33 A LYS 34 n 34 LYS 34 A ILE 35 n 35 ILE 35 A ARG 36 n 36 ARG 36 A LEU 37 n 37 LEU 37 A ASP 38 n 38 ASP 38 A THR 39 n 39 THR 39 A GLU 40 n 40 GLU 40 A n 41 41 A n 42 42 A GLY 43 n 43 GLY 43 A VAL 44 n 44 VAL 44 A PRO 45 n 45 PRO 45 A SER 46 n 46 SER 46 A THR 47 n 47 THR 47 A ALA 48 n 48 ALA 48 A ILE 49 n 49 ILE 49 A ARG 50 n 50 ARG 50 A GLU 51 n 51 GLU 51 A ILE 52 n 52 ILE 52 A SER 53 n 53 SER 53 A LEU 54 n 54 LEU 54 A LEU 55 n 55 LEU 55 A LYS 56 n 56 LYS 56 A GLU 57 n 57 GLU 57 A LEU 58 n 58 LEU 58 A ASN 59 n 59 ASN 59 A HIS 60 n 60 HIS 60 A PRO 61 n 61 PRO 61 A ASN 62 n 62 ASN 62 A ILE 63 n 63 ILE 63 A VAL 64 n 64 VAL 64 A LYS 65 n 65 LYS 65 A LEU 66 n 66 LEU 66 A LEU 67 n 67 LEU 67 A ASP 68 n 68 ASP 68 A VAL 69 n 69 VAL 69 A ILE 70 n 70 ILE 70 A HIS 71 n 71 HIS 71 A THR 72 n 72 THR 72 A GLU 73 n 73 GLU 73 A ASN 74 n 74 ASN 74 A LYS 75 n 75 LYS 75 A LEU 76 n 76 LEU 76 A TYR 77 n 77 TYR 77 A LEU 78 n 78 LEU 78 A VAL 79 n 79 VAL 79 A PHE 80 n 80 PHE 80 A GLU 81 n 81 GLU 81 A PHE 82 n 82 PHE 82 A LEU 83 n 83 LEU 83 A HIS 84 n 84 HIS 84 A GLN 85 n 85 GLN 85 A ASP 86 n 86 ASP 86 A LEU 87 n 87 LEU 87 A LYS 88 n 88 LYS 88 A LYS 89 n 89 LYS 89 A PHE 90 n 90 PHE 90 A MET 91 n 91 MET 91 A ASP 92 n 92 ASP 92 A ALA 93 n 93 ALA 93 A SER 94 n 94 SER 94 A ALA 95 n 95 ALA 95 A LEU 96 n 96 LEU 96 A THR 97 n 97 THR 97 A GLY 98 n 98 GLY 98 A ILE 99 n 99 ILE 99 A PRO 100 n 100 PRO 100 A LEU 101 n 101 LEU 101 A PRO 102 n 102 PRO 102 A LEU 103 n 103 LEU 103 A ILE 104 n 104 ILE 104 A LYS 105 n 105 LYS 105 A SER 106 n 106 SER 106 A TYR 107 n 107 TYR 107 A LEU 108 n 108 LEU 108 A PHE 109 n 109 PHE 109 A GLN 110 n 110 GLN 110 A LEU 111 n 111 LEU 111 A LEU 112 n 112 LEU 112 A GLN 113 n 113 GLN 113 A GLY 114 n 114 GLY 114 A LEU 115 n 115 LEU 115 A ALA 116 n 116 ALA 116 A PHE 117 n 117 PHE 117 A CYS 118 n 118 CYS 118 A HIS 119 n 119 HIS 119 A SER 120 n 120 SER 120 A HIS 121 n 121 HIS 121 A ARG 122 n 122 ARG 122 A VAL 123 n 123 VAL 123 A LEU 124 n 124 LEU 124 A HIS 125 n 125 HIS 125 A ARG 126 n 126 ARG 126 A ASP 127 n 127 ASP 127 A LEU 128 n 128 LEU 128 A LYS 129 n 129 LYS 129 A PRO 130 n 130 PRO 130 A GLN 131 n 131 GLN 131 A ASN 132 n 132 ASN 132 A LEU 133 n 133 LEU 133 A LEU 134 n 134 LEU 134 A ILE 135 n 135 ILE 135 A ASN 136 n 136 ASN 136 A THR 137 n 137 THR 137 A GLU 138 n 138 GLU 138 A GLY 139 n 139 GLY 139 A ALA 140 n 140 ALA 140 A ILE 141 n 141 ILE 141 A LYS 142 n 142 LYS 142 A LEU 143 n 143 LEU 143 A ALA 144 n 144 ALA 144 A ASP 145 n 145 ASP 145 A PHE 146 n 146 PHE 146 A GLY 147 n 147 GLY 147 A LEU 148 n 148 LEU 148 A ALA 149 n 149 ALA 149 A ARG 150 n 150 ARG 150 A ALA 151 n 151 ALA 151 A PHE 152 n 152 PHE 152 A GLY 153 n 153 GLY 153 A VAL 154 n 154 VAL 154 A PRO 155 n 155 PRO 155 A VAL 156 n 156 VAL 156 A ARG 157 n 157 ARG 157 A THR 158 n 158 THR 158 A TYR 159 n 159 TYR 159 A THR 160 n 160 THR 160 A HIS 161 n 161 HIS 161 A GLU 162 n 162 GLU 162 A VAL 163 n 163 VAL 163 A VAL 164 n 164 VAL 164 A THR 165 n 165 THR 165 A LEU 166 n 166 LEU 166 A TRP 167 n 167 TRP 167 A TYR 168 n 168 TYR 168 A ARG 169 n 169 ARG 169 A ALA 170 n 170 ALA 170 A PRO 171 n 171 PRO 171 A GLU 172 n 172 GLU 172 A ILE 173 n 173 ILE 173 A LEU 174 n 174 LEU 174 A LEU 175 n 175 LEU 175 A GLY 176 n 176 GLY 176 A CYS 177 n 177 CYS 177 A LYS 178 n 178 LYS 178 A TYR 179 n 179 TYR 179 A TYR 180 n 180 TYR 180 A SER 181 n 181 SER 181 A THR 182 n 182 THR 182 A ALA 183 n 183 ALA 183 A VAL 184 n 184 VAL 184 A ASP 185 n 185 ASP 185 A ILE 186 n 186 ILE 186 A TRP 187 n 187 TRP 187 A SER 188 n 188 SER 188 A LEU 189 n 189 LEU 189 A GLY 190 n 190 GLY 190 A CYS 191 n 191 CYS 191 A ILE 192 n 192 ILE 192 A PHE 193 n 193 PHE 193 A ALA 194 n 194 ALA 194 A GLU 195 n 195 GLU 195 A MET 196 n 196 MET 196 A VAL 197 n 197 VAL 197 A THR 198 n 198 THR 198 A ARG 199 n 199 ARG 199 A ARG 200 n 200 ARG 200 A ALA 201 n 201 ALA 201 A LEU 202 n 202 LEU 202 A PHE 203 n 203 PHE 203 A PRO 204 n 204 PRO 204 A GLY 205 n 205 GLY 205 A ASP 206 n 206 ASP 206 A SER 207 n 207 SER 207 A GLU 208 n 208 GLU 208 A ILE 209 n 209 ILE 209 A ASP 210 n 210 ASP 210 A GLN 211 n 211 GLN 211 A LEU 212 n 212 LEU 212 A PHE 213 n 213 PHE 213 A ARG 214 n 214 ARG 214 A ILE 215 n 215 ILE 215 A PHE 216 n 216 PHE 216 A ARG 217 n 217 ARG 217 A THR 218 n 218 THR 218 A LEU 219 n 219 LEU 219 A GLY 220 n 220 GLY 220 A THR 221 n 221 THR 221 A PRO 222 n 222 PRO 222 A ASP 223 n 223 ASP 223 A GLU 224 n 224 GLU 224 A VAL 225 n 225 VAL 225 A VAL 226 n 226 VAL 226 A TRP 227 n 227 TRP 227 A PRO 228 n 228 PRO 228 A GLY 229 n 229 GLY 229 A VAL 230 n 230 VAL 230 A THR 231 n 231 THR 231 A SER 232 n 232 SER 232 A MET 233 n 233 MET 233 A PRO 234 n 234 PRO 234 A ASP 235 n 235 ASP 235 A TYR 236 n 236 TYR 236 A LYS 237 n 237 LYS 237 A PRO 238 n 238 PRO 238 A SER 239 n 239 SER 239 A PHE 240 n 240 PHE 240 A PRO 241 n 241 PRO 241 A LYS 242 n 242 LYS 242 A TRP 243 n 243 TRP 243 A ALA 244 n 244 ALA 244 A ARG 245 n 245 ARG 245 A GLN 246 n 246 GLN 246 A ASP 247 n 247 ASP 247 A PHE 248 n 248 PHE 248 A SER 249 n 249 SER 249 A LYS 250 n 250 LYS 250 A VAL 251 n 251 VAL 251 A VAL 252 n 252 VAL 252 A PRO 253 n 253 PRO 253 A PRO 254 n 254 PRO 254 A LEU 255 n 255 LEU 255 A ASP 256 n 256 ASP 256 A GLU 257 n 257 GLU 257 A ASP 258 n 258 ASP 258 A GLY 259 n 259 GLY 259 A ARG 260 n 260 ARG 260 A SER 261 n 261 SER 261 A LEU 262 n 262 LEU 262 A LEU 263 n 263 LEU 263 A SER 264 n 264 SER 264 A GLN 265 n 265 GLN 265 A MET 266 n 266 MET 266 A LEU 267 n 267 LEU 267 A HIS 268 n 268 HIS 268 A TYR 269 n 269 TYR 269 A ASP 270 n 270 ASP 270 A PRO 271 n 271 PRO 271 A ASN 272 n 272 ASN 272 A LYS 273 n 273 LYS 273 A ARG 274 n 274 ARG 274 A ILE 275 n 275 ILE 275 A SER 276 n 276 SER 276 A ALA 277 n 277 ALA 277 A LYS 278 n 278 LYS 278 A ALA 279 n 279 ALA 279 A ALA 280 n 280 ALA 280 A LEU 281 n 281 LEU 281 A ALA 282 n 282 ALA 282 A HIS 283 n 283 HIS 283 A PRO 284 n 284 PRO 284 A PHE 285 n 285 PHE 285 A PHE 286 n 286 PHE 286 A GLN 287 n 287 GLN 287 A ASP 288 n 288 ASP 288 A VAL 289 n 289 VAL 289 A THR 290 n 290 THR 290 A LYS 291 n 291 LYS 291 A PRO 292 n 292 PRO 292 A VAL 293 n 293 VAL 293 A PRO 294 n 294 PRO 294 A HIS 295 n 295 HIS 295 A LEU 296 n 296 LEU 296 A ARG 297 n 297 ARG 297 A LEU 298 n 298 LEU 298 A author_and_software_defined_assembly PISA 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N GLY 13 A N GLY 13 A O GLY 16 A O GLY 16 A N ALA 21 A N ALA 21 A O VAL 30 A O VAL 30 A N LYS 33 A N LYS 33 A O LEU 78 A O LEU 78 A O VAL 79 A O VAL 79 A N LEU 67 A N LEU 67 A N GLN 85 A N GLN 85 A O ILE 135 A O ILE 135 A N LEU 134 A N LEU 134 A O LYS 142 A O LYS 142 1 A CD GLU 40 A CD GLU 40 1 Y 1 A OE1 GLU 40 A OE1 GLU 40 1 Y 1 A OE2 GLU 40 A OE2 GLU 40 1 Y 1 A THR 41 A THR 41 1 Y 1 A GLU 42 A GLU 42 1 Y 1 A A CG2 CD1 ILE ILE 135 141 2.08 B 1 A A O O HOH HOH 2047 2048 2.13 1 A LEU 175 10.03 1 A A ASN LYS 74 75 -134.64 1 10.40 1.70 111.00 121.40 A A A CB CG CD1 LEU LEU LEU 267 267 267 N 1 A THR 14 59.83 -48.90 1 A ASP 38 -41.55 -19.55 1 A PRO 45 -39.17 140.16 1 A GLU 73 51.10 -129.05 1 A ARG 126 85.82 -18.04 1 A ASP 127 -144.11 49.30 1 A ASP 145 73.43 53.28 1 A THR 158 52.70 -169.73 1 A HIS 161 86.67 -4.21 1 A TYR 179 -105.43 50.48 1 A LEU 255 -38.49 136.89 39.293 -0.66 0.00 0.00 2.33 0.00 -1.68 0.962 0.918 HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. RESIDUES 340-42 ARE DISORDED. DISORDERED REGIONS WERE MODELED STEREOCHEMICALLY 13-18, 147-163. 0.29378 0.21279 0.21557 1.85 30.00 766 22795 3.3 98.74 6.508 0.189 RANDOM 1 THROUGHOUT MOLECULAR REPLACEMENT 0.196 0.193 0.80 0.80 1.20 PDB ENTRY 2CLX MAXIMUM LIKELIHOOD BABINET MODEL WITH MASK 1.85 30.00 260 2666 27 0 2379 0.012 0.022 2612 0.003 0.020 1839 1.689 1.999 3563 0.943 3.002 4454 8.852 5.000 323 41.472 22.768 112 21.963 15.000 468 24.623 15.000 20 0.126 0.200 391 0.017 0.021 2852 0.001 0.020 534 3.229 1.500 1527 1.146 1.500 603 4.610 2.000 2502 6.294 3.000 1085 8.205 4.500 1046 0.477 0.450 1.898 60 1661 20 99.65 1.80 31.88 2XNB 25565 2.0 0.08 1 7.30 2.63 98.8 0.48 1.80 1.86 2.10 1 2.56 99.1 refinement REFMAC 5.5.0109 data reduction d*TREK data scaling d*TREK phasing MOLREP Discovery and Characterisation of 2-Anilino-4-(thiazol-5-yl) pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents 1 N N 2 N N 3 N N A PRO 45 A PRO 45 HELX_P A LYS 56 A LYS 56 1 1 12 A LEU 87 A LEU 87 HELX_P A SER 94 A SER 94 1 2 8 A PRO 100 A PRO 100 HELX_P A HIS 121 A HIS 121 1 3 22 A GLY 147 A GLY 147 HELX_P A PHE 152 A PHE 152 1 4 6 A ALA 170 A ALA 170 HELX_P A LEU 175 A LEU 175 1 5 6 A THR 182 A THR 182 HELX_P A ARG 199 A ARG 199 1 6 18 A SER 207 A SER 207 HELX_P A GLY 220 A GLY 220 1 7 14 A GLY 229 A GLY 229 HELX_P A MET 233 A MET 233 5 8 5 A ASP 247 A ASP 247 HELX_P A VAL 252 A VAL 252 1 9 6 A ASP 256 A ASP 256 HELX_P A LEU 267 A LEU 267 1 10 12 A SER 276 A SER 276 HELX_P A LEU 281 A LEU 281 1 11 6 A ALA 282 A ALA 282 HELX_P A GLN 287 A GLN 287 5 12 6 TRANSFERASE CELL CYCLE, TRANSFERASE, CDK9 INHIBITOR A PRO 253 A PRO 253 1 A PRO 254 A PRO 254 8.16 CDK2_HUMAN UNP 1 P24941 1 298 2XNB 1 298 P24941 A 1 1 298 5 3 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel A PHE 4 A PHE 4 A GLY 13 A GLY 13 A GLY 16 A GLY 16 A ASN 23 A ASN 23 A VAL 29 A VAL 29 A LYS 34 A LYS 34 A LYS 75 A LYS 75 A GLU 81 A GLU 81 A LEU 66 A LEU 66 A THR 72 A THR 72 A GLN 85 A GLN 85 A ASP 86 A ASP 86 A LEU 133 A LEU 133 A ILE 135 A ILE 135 A ILE 141 A ILE 141 A LEU 143 A LEU 143 BINDING SITE FOR RESIDUE Y8L A 1299 A Y8L 1299 Software 15 A ILE 10 A ILE 10 15 1_555 A GLU 12 A GLU 12 15 1_555 A VAL 18 A VAL 18 15 1_555 A ALA 31 A ALA 31 15 1_555 A LYS 33 A LYS 33 15 1_555 A PHE 80 A PHE 80 15 1_555 A GLU 81 A GLU 81 15 1_555 A LEU 83 A LEU 83 15 1_555 A HIS 84 A HIS 84 15 1_555 A GLN 85 A GLN 85 15 1_555 A ASP 86 A ASP 86 15 1_555 A LEU 134 A LEU 134 15 1_555 A ASP 145 A ASP 145 15 1_555 A HOH 2006 C HOH 15 1_555 A HOH 2258 C HOH 15 1_555 19 P 21 21 21